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The treatment of acute coronary syndromes (ACS) is currently undergoing an interesting
evolution due to the introduction of some novel antithrombotic drugs. The available evidence
on new oral antiplatelet agents can be summarized as follows: (1) the new drugs (prasugrel
and ticagrelor) are faster, more potent, and more predictable than clopidogrel, and thus
prasugrel or ticagrelor may replace clopidogrel in most patients with ACS; (2) prasugrel seems
to have a more pronounced acute effect, especially in patients with acute ST-elevation
myocardial infarction (STEMI), and thus prasugrel may be the preferred drug for STEMI,
especially for the acute phase; (3) ticagrelor seems to have better secondary preventive effects
in the long term, which may be advantageous for patients with acute non-STEMI; and (4) both
new drugs have some contraindications or unpleasant side effects and are both substantially
more expensive, which may keep a place in therapy for clopidogrel for selected patients.
& 2012 The Czech Society of Cardiology. Published by Elsevier Urban & Partner Sp.z.o.o. All
rights reserved.1. ACS epidemiology
Acute coronary syndromes (ACS; acute ST-elevation myocar-
dial infarction [STEMI], acute non-STEMI, and unstable
angina pectoris [UAP]) are the single most frequent cause of
death worldwide [1]. The CZECH (Czech Evaluation of Acute
Coronary Syndromes in Hospitalized Patients) registry, which
covered 100% of hospital admissions in 100% of hospitals in
two large counties, found the incidence of hospital admissionch Society of Cardiology.
21; fax: þ420 267 162 525
Widimsky)for suspected ACS to be 3248 patients per million inhabitants
per year. The incidence of confirmed acute myocardial
infarction (MI; STEMI and non-STEMI) was 1960 patients/
million/year [2]. The second Euro Heart Survey [3], performed
in 190 selected (voluntary participation) medical centers in 32
countries, enrolled 6385 patients with a confirmed diagnosis
of ACS, with 47% of participants suffering from STEMI and
53% from non-STEMI or UAP. The incidence could not be
calculated as the Euro Heart Survey did not cover any definedPublished by Elsevier Urban & Partner Sp.z.o.o. All rights reserved.
.
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30 countries [4] have shown the annual incidence of hospital
admission for any acute MI to be 900–3120 patients/million/
year, with the incidence of STEMI alone ranging from 440 to
1420 patients/million/year. The in-hospital mortality of pa-
tients with acute MI varied between 4% and 14% in different
national registries.
In the United States, the CRUSADE (Can Rapid Risk
Stratification of Unstable Angina Patients Suppress Adverse
OutcomesWith Early Implementation of the ACC/AHAGuide-
lines) registry [5] enrolled 17,926 high-risk patients with non-
STEMI/UAP; the mean age of patients was 68 years, 32% had
diabetes, and 13% had renal insufficiency. In-hospital mor-
tality was 2% when the early invasive strategy was applied
and 6.2% when it was not applied. Thus, ACS remains a
frequent and serious illness even in the modern ‘‘interven-
tional era.’’ However, new treatment options that improve
acute and long-term outcomes are still needed. While the first
decade of the 21st century from the ACS perspective can be
called the ‘‘decade of percutaneous interventions,’’ at the
beginning of the second decade we are facing major devel-
opments in antithrombotic therapies. The new antiplatelet
and anticoagulant drugs have the potential to substantially
modify the ‘‘field.’’ This article focuses on the new oral
antiplatelet agents in the management of patients with ACS.2. Historical evolution of oral antiplatelet
therapy
Aspirin was the first antiplatelet drug with proven benefit in
ACS and in secondary prevention [6,7]. The beneficial effects
of aspirin are so widely accepted that there has been only one
randomised trial [8] in the past 20 years that tested a new
antiplatelet agent versus aspirin. This trial demonstrated that
clopidogrel alone is approximately 9% more effective than
aspirin alone and has approximately 30% less bleeding
complications. However, after publication of the CURE
(Clopidogrel in Unstable Angina to Prevent Recurrent Events)
study [9], dual oral antiplatelet therapy became the new
standard. Since that time, all newly developed oral antiplate-
let agents were tested against clopidogrel, with aspirin left as
the baseline therapy, in both arms of all randomised trials.
After the failure of several oral glycoprotein IIb/IIIa inhibitors
(e.g., sibrafiban) [10], the development of antiplatelet agents has
focused on novel P2Y12 receptor blockers (P2Y12 inhibitors). The
first two drugs from this family are already registered for use in
Europe (prasugrel and ticagrelor), while others (e.g., elinogrel
and cangrelor) are still under development.3. Recent developments in antiplatelet
therapy
Prasugrel (a third-generation thienopyridine) is the first drug
from this ‘‘family’’ of new oral antiplatelet agents. It is a prodrug
that (like clopidogrel) requires conversion to an activemetabolite
before irreversible binding to the platelet P2Y12 receptor.
Prasugrel inhibits adenosine diphosphate (ADP)-induced platelet
aggregation more rapidly, more consistently (low inter-patientvariability), and to a greater extent than clopidogrel [11]. The
TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic
Outcomes by Optimizing Platelet Inhibition with Prasugrel-
Thrombolysis in Myocardial Infarction 38) trial [12] provided
evidence that prasugrel and aspirin are superior to clopidogrel
and aspirin in patients with ACS undergoing percutaneous
coronary intervention (PCI). The benefit was especially pro-
nounced in patients with STEMI [13] and in patients with
diabetes mellitus [14]. A recent study [15] that evaluated
switching patients from clopidogrel therapy to prasugrel demon-
strated further reduction in platelet function by 1 week using
a prasugrel maintenance dose or within 2 h after administration
of a prasugrel loading dose. Another study [16] has shown that
a prasugrel maintenance dose of 10mg resulted in significantly
greater platelet inhibition than a double clopidogrel mainte-
nance dose (150mg) or a high clopidogrel loading dose (600mg).
This is an important observation, as the TRITON-TIMI 38
study compared prasugrel against the ‘‘classic’’ clopidogrel dose
(a loading dose of 300mg and a maintenance dose of 75mg).
Ticagrelor differs from the classic thienopyridines (ticlopi-
dine, clopidogrel, and prasugrel) because it is a cyclo-pentyl-
triazolo-pyrimidine that also targets the P2Y12 receptor [17].
Unlike the thienopyridines, however, it is a direct-acting
reversibly binding inhibitor with a half-life of approximately
12 h, which does not require metabolic activation [18]. In the
PLATO (Platelet Inhibition and Patient Outcomes) trial [19],
ticagrelor was shown to be superior to clopidogrel. The
primary endpoint (death from vascular causes, MI, or stroke)
occurred in 9.8% of patients receiving ticagrelor and in 11.7%
of those receiving clopidogrel (hazard ratio [HR], 0.84; 95%
confidence interval [CI], 0.77–0.92; Po0.001). The rate of death
from any cause was also reduced with ticagrelor (4.5% versus
5.9% with clopidogrel; Po0.001). Among the subgroup of over
7000 patients with STEMI [20], there was a strong trend that
ticagrelor reduced the primary endpoint (MI, stroke, or
cardiovascular death) from 10.8% with clopidogrel to 9.4%
with ticagrelor (HR, 0.87; 95% CI, 0.75–1.01; P ¼ 0.07). This is a
slightly lower benefit than in the entire PLATO trial popula-
tion. Overall, ticagrelor did not increase bleeding events
compared to clopidogrel. However, bleeding was mainly
driven by coronary artery bypass grafting (CABG)-associated
bleedings, and non-CABG-associated bleedings were signifi-
cantly higher with ticagrelor. A significant proportion of the
PLATO cohort underwent CABG. Interestingly, ticagrelor was
also superior to clopidogrel in the subgroup of patients with
ACS without significant excess bleeding, which is probably
due to the reversible binding to the ADP receptor [21].
A major recent finding of these more potent P2Y12
inhibitors is their ability to decrease mortality compared with
clopidogrel when used in patients treated with PCI. This is
especially observed in patients with STEMI treated by PCI
or by primary PCI, a group at higher risk and therefore
theoretically obtaining greater benefit from rapid platelet
inhibition for PCI. Indeed, the net benefit is particularly
favorable with a significant reduction in cardiovascular
mortality (OR ¼ 0.81; 95% CI, 0.69–0.95; P ¼ 0.008) and stent
thrombosis (OR, 0.66; 95% CI, 0.53–0.83; Po0.0001), without
excess of major bleeding (OR, 0.98; 95% CI, 0.85–1.13; P ¼ 0.76).
A recent adjusted, indirect meta-analysis [22] attempted to
compare the novel agents (prasugrel or ticagrelor) versus
C O R E T VA S A 54 ( 2012 ) e32 –e38e34clopidogrel, while also comparing the two new agents against
each other. This analysis has significant limitations; in fact,
these two studies are not comparable because of the major
differences in the inclusion criteria and in the definition of
bleeding. Overall, both prasugrel and ticagrelor appeared
significantly superior to clopidogrel for the 12-month risk
of stroke (OR ¼ 0.83; 95% CI, 0.77–0.89; Po0.001), death
(OR ¼ 0.83, 95% CI, 0.74–0.93; P ¼ 0.001), MI (OR ¼ 0.79; 95%
CI, 0.73–0.86; Po0.001), and stent thrombosis (OR ¼ 0.61; 95%
CI, 0.51–0.74; Po0.001), without any significant difference in
stroke or major bleeding (both P40.05). Head-to-head com-
parison of prasugrel versus ticagrelor showed no significant
differences in overall death, MI, stroke, or their composite
(all P40.05). Prasugrel was associated with a significantly
lower risk of stent thrombosis (OR ¼ 0.64; 95% CI, 0.43–0.93;
P ¼ 0.020). Ticagrelor was associatedwith a significantly lower
risk of any major bleeding (OR ¼ 1.43; 95% CI, 1.10–1.85;
P ¼ 0.007) and CABG-associated major bleeding (OR ¼ 4.30;
95% CI, 1.73–10.6; P ¼ 0.002). However, the more clinically
relevant risk of non-CABG-associated major bleeding was
similar with either prasugrel or ticagrelor (OR ¼ 1.06; 95% CI,
0.77–1.45; P ¼ 0.34).
A recent in vitro study [23] introduced the provocative
question of whether there is still need for aspirin in the
coming era of potent P2Y12 inhibitors. Strong P2Y12 receptor
blockade alone causes inhibition of platelet aggregation,
which is enhanced little by aspirin. However, the clinical
relevance of these observations remains to be determined.4. Variability in response to antiplatelet
agents
The most important limitation of clopidogrel efficacy is the
inter-patient variability of its antiplatelet effects, caused –
among others – by genetic variations of cytochrome P450 2C19
(CYP2C19) [24]. Moreover, clopidogrel and prasugrel are
subject to efflux via P-glycoprotein that is encoded by ABCB1,
also known as MDR1. ABCB1 polymorphisms, particularly
3435C-T, may affect drug transport and efficacy. A recent
study by Mega and colleagues [25] evaluated the effect of this
polymorphism alone and alongside reduced-function alleles
of CYP2C19 on cardiovascular outcomes in 2932 patients with
ACS undergoing PCI treated with clopidogrel or prasugrel. The
effect of genotypes on the pharmacodynamic and pharma-
cokinetic properties of these drugs in 321 healthy individuals
was also evaluated. In patients treated with clopidogrel, the
ABCB1 3435C-T genotype was significantly associated with
the risk of cardiovascular death, MI, or stroke (P ¼ 0.0064).
ABCB1 3435C-T and CYP2C19 genotypes were significant,
independent predictors of the primary endpoint. ABCB1
genotypes were not significantly associated with clinical or
pharmacological outcomes in patients with ACS or healthy
individuals treated with prasugrel, respectively. In patients
with ACS who have undergone PCI, when both ABCB1 and
CYP2C19 are taken into account, nearly half of the population
carries a genotype associated with increased risk of major
adverse cardiovascular events while on standard doses of
clopidogrel.The impact of CYP2C19 and ABCB1 genotypes on outcomes
between and within groups treated with either ticagrelor or
clopidogrel was investigated in the genetic substudy of the
PLATO study [26]. However, routine genotype testing is not
recommended in clinical practice. The primary composite
endpoint of cardiovascular death, MI, or stroke occurred less
often with ticagrelor versus clopidogrel, irrespective of
CYP2C19 genotype. For the ABCB1 genotype, event rates for
the primary outcome were also consistently lower in the
ticagrelor than in the clopidogrel group.5. Platelet reactivity testing
A recently published consensus paper summarized the
evidence for the association between on-treatment platelet
reactivity to ADP measured by multiple methods and adverse
clinical events, which was extracted from 28 clinical studies
with more than 11,000 patients [27]. Despite an overwhelming
body of evidence, routine measurement of platelet reactivity
has not been widely implemented and recommended in the
guidelines. Reasons for the latter include a lack of consensus
on the optimal method to quantify high on-treatment platelet
reactivity, which disables provision of a uniform cutoff value
associated with clinical risk for ischemic events. Data for
linking superior antiplatelet response to an increased risk of
bleeding are even more sparse. Currently, only limited clinical
data show an improved outcome by personalized tailored
antiplatelet therapy, i.e., dose adaptation based on platelet
function measurements.
The GRAVITAS (Gauging Responsiveness With a VerifyNow
Assay-Impact on Thrombosis and Safety) study [28] failed to
show an improvement in clinical outcome for patients after
PCI with an intensified clopidogrel regimen. Patients with
high on-treatment platelet reactivity after standard clopido-
grel dosing were randomized to either clopidogrel 75 mg daily
or to an intensified antiplatelet regimen using clopidogrel
150 mg daily. The increase in clopidogrel dose, however, did
not transfer into clinical benefit. The primary endpoint
occurred in 2.3% in both groups: those with increased
clopidogrel dose (600-mg loading dose followed by 150-mg
maintenance dose) and in those who remained on the
standard dose (300-mg loading dose followed by 75-mg
maintenance dose). The reduction in platelet reactivity
caused by the increased clopidogrel dosing in GRAVITAS
was small, and further studies like TRIGGER-PCI (Testing
Platelet Reactivity in Patients Undergoing Elective Stent
Placement on Clopidogrel to Guide Alternative Therapy With
Prasugrel), which compare more efficacious antiplatelet regi-
mens (prasugrel 10 mg versus clopidogrel 75 mg), may
validate this concept.6. Current guideline recommendations for
oral antiplatelet therapy
The most recent European Society of Cardiology (ESC) guide-
lines [29] recommend prasugrel or ticagrelor plus aspirin for
the majority of patients with STEMI. Clopidogrel is considered
Table 2 – ACC/AHA [30,31] and ESC [29] Recommenda-
tions for Antiplatelet Therapy in Patients Undergoing
Myocardial Revascularisation.
Elective PCI (ESC)a Aspirin 150–300 mg/day orally (or 250–500 mg
bolus IV) then 75–100 mg/day plus:
 Clopidogrel: 300-mg LD 46 h before PCI
(or 600 mg 42 h before) then 75 mg/day
(class I level C)
NSTE-ACS (ESC)a UAP/non-
STEMI (ACC/AHA) [30,31]
Aspirin 150–300 mg/day orally (or 250–500 mg
bolus IV) then 75–100 mg/day plus one of:
 Clopidogrel: 600-mg LD as soon as possible
(class I level C) then 75 mg/day for 9–12
months after PCI (class I level B)
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the faster-acting and more potent P2Y12 inhibitors are
contraindicated, or if the new drugs are not yet approved. In
patients with non-STEMI, all three drugs are considered to be
equivalent alternatives by these guidelines (see Table 1).
The American College of Cardiology (ACC)/American Heart
Association (AHA) guidelines for STEMI from 2009 [30]
recommend either clopidogrel (300–600-mg loading dose
followed by 75-mg maintenance dose) or prasugrel (60-mg
loading dose followed by 10-mg maintenance dose) before
and after primary PCI. A more detailed overview of oral
antiplatelet therapy dosage in the ESC and ACC/AHA guide-
lines is presented in Table 2.
 Prasugrel: 60-mg LD then 10 mg/day
(class IIa level B)
 Ticagrelor: b 180-mg LD then 90 mg bid
(class I level B)
In patients selected for an invasive strategy
[30], aspirin should be initiated upon
presentation (class I level A) plus one of:
 Clopidogrel: before [pre-loading] or at the
time of PCI (300-mg LD then 75 mg/day;
class I level A)
 Prasugrel: at the time of PCI (60-mg LD
then 10 mg/day; class I level B)
In patients selected for an initial
conservative strategy [31], aspirin should be
initiated as soon as possible after admission
plus: Clopidogrel: 300-mg LD then 75 mg/day
should be added as soon as possible after
admission for Z1 month (class IA) to r12
months (class I level B)7. New strategies for optimal treatment of ACS
(including STEMI)
The available evidence can be summarized as follows: (1) both
new drugs (prasugrel and ticagrelor) provide faster, more
potent, and more predictable antiplatelet effects than clopi-
dogrel, and thus prasugrel or ticagrelor may replace clopido-
grel in most patients with ACS; (2) the beneficial effect of
prasugrel, if comparedwith clopidogrel, is achieved early with
a superior efficacy in patients with STEMI, especially in the
acute phase, and thus prasugrel may be the preferred drug in
patients with STEMI undergoing early PCI; (3) ticagrelor seems
to have better secondary preventive effects in the long term,
which may be advantageous for patients with non-STEMI
(who have lower risk acutely, but higher risk in the long-term
compared to STEMI); and (4) both new drugs have some
contraindications or unpleasant side effects and are bothTable 1 – The European Society of Cardiology recom-
mendations for the use of oral antiplatelet therapies.
P2Y12 inhibitor Class
a Levelb
Non-STEMI/UAP
Clopidogrel I B
Prasugrel IIa B
Ticagrelor I B
STEMI
Clopidogrel I C
Prasugrel I B
Ticagrelor I B
STEMI, ST-elevation myocardial infarction; UAP, unstable angina
pectoris.
Adapted from Wijns, 2010. European Heart Journal. 31 (20),
2501–2555 [29].
a Class I recommendation: Evidence and/or general agreement
that a given treatment or procedure is beneficial, useful, and
effective; Class IIa recommendation: weight of evidence/opinion
is in favor of usefulness/efficacy.
b Level B recommendation: data derived from a single randomised
clinical trial or large non-randomised trials; Level C recommen-
dation: consensus of opinion of the experts and/or small studies,
retrospective studies, and registries.
STEMI (ESC/ACC)ac Aspirin 150–300 mg/day orally (or 250–500 mg
bolus IV) then 75–100 mg/day plus one of:
 Clopidogrel: 600-mg LD as soon as possible
then 75 mg/day for 9–12 months after PCId
(class I level C)
 Prasugrel: 60-mg LD then 10 mg/dayd
(class I level B)
 Ticagrelor:b 180-mg LD then 90 mg bid
(class I level B)
ACC/AHA, American College of Cardiology/American Heart Asso-
ciation; ACS, acute coronary syndrome; bid, twice daily; ESC,
European Society of Cardiology; IV, intravenous; NSTE-ACS, non-
ST-segment-elevation ACS; PCI, percutaneous coronary interven-
tion; STEMI, ST-elevation myocardial infarction; UAP, unstable
angina pectoris.
a Additional glycoprotein (GP) IIb/IIIa antagonist therapy (including
abciximab, tirofiban, eptifibatide, and upstream GP IIb/IIIa
antagonists) in patients with evidence of high intracoronary
thrombus burden (NSTE-ACS and STEMI patients) or as a bailout
situation only (PCI patients) is recommended in EU guidelines
[29]. In the US, abciximab, tirofiban, and eptifibatide can be
initiated at the time in selected PCI patients.
b Ticagrelor is recommended (depending on availability) in EU
guidelines only [29].
c In the US guidelines, in patients pretreated with thienopyridines
requiring coronary artery bypass grafting, surgery should be
postponed for 5 days in patients receiving clopidogrel and 7 days
in patients receiving prasugrel, if clinically feasible.
d Loading dose (LD) of clopidogrel should be given as early as
possible or at the time of primary or nonprimary PCI; LD of
prasugrel should be given as soon as possible for primary PCI.
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therapy for clopidogrel for selected patients. This is summar-
ized in Table 3.Table 3 – Dose recommendations for oral antiplatelet
therapies.
Loading dose Maintenance
dose
Non-STEMI/UAP
First medical
contact (pre-
hospital or
hospital
emergency)
Clopidogrel
300–600 mg or
Ticagrelor 180 mg (or
Prasugrel 60 mg)
Periprocedural (in
the
catheterisation
lab)
When no P2Y12
inhibitor was given
previously:
Prasugrel 60 mg or
Ticagrelor 180 mg or
Clopidogrel
300–600 mg
Secondary
prevention (after
PCI until 1 year
later)
Ticagrelor 90 mg
twice/day or
Prasugrel 10 mg
once/day or
Clopidogrel 75 mg
once/day
STEMI
First medical
contact (pre-
hospital or
hospital
emergency)
Prasugrel 60 mg (or
Ticagrelor 180mg or
Clopidogrel 600 mg)
Periprocedural (in
the
catheterisation
lab)
When no P2Y12
inhibitor was given
previously:
Prasugrel 60 mg (or
Ticagrelor 180mg or
Clopidogrel 600mg)
Secondary
prevention (after
PCI until 1 year
later)
Prasugrel 10 mg
once/day or
Ticagrelor 90 mg
twice/day (or
Clopidogrel 75 mg
once/day)
Stent thrombosis
Prasugrel 60 mg at
the time of
diagnosis
Prasugrel 10 mg
for Z12 months
Perioperative setting (around CABG)
CABG should be performed on the elective basis for 47 days after
the early coronary angiography whenever the patient is stable
without recurrent ischemia. Either drug (clopidogrel, prasugrel, or
ticagrelor) should be stopped 5–7 days prior to such elective bypass
surgery. When CABG must be performed earlier due to patient
instability (recurrent ischemia), platelet concentrates usually
correct the bleeding problems. Most modern cardiac surgeons are
accustomed to operating on patients on antiplatelet agents.
CABG, coronary artery bypass grafting; PCI, percutaneous coronary
intervention; STEMI, ST-elevation myocardial infarction; UAP,
unstable angina pectoris.8. Conclusions
The availability of new, more potent, and faster-acting oral
antiplatelet agents is currently changing the treatment of ACS
in that they may replace clopidogrel in the majority of
patients with ACS. Either prasugrel or ticagrelor provide
(independently of genetic factors) superior and more pre-
dictable antiplatelet effects than clopidogrel, resulting in an
improved outcome for patients with ACS. This holds espe-
cially true for the treatment of patients with STEMI and
diabetes, and for the prevention of stent thrombosis. Finally,
evidence is still lacking to support the widespread use of
platelet function testing to guide oral antiplatelet therapy.
Ongoing studies are needed to investigate the relationship of
platelet reactivity to bleeding events.Acknowledgments
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